Merus (NASDAQ:MRUS) Reaches New 1-Year Low – Should You Sell?

Shares of Merus (NASDAQ:MRUS) hit a new 52-week low during trading on Friday . The company traded as low as $37.54 and last traded at $37.87, with a volume of 438895 shares. The stock had previously closed at $41.73.

Analyst Ratings Changes

Several research analysts recently commented on MRUS shares. Bank of America cut their price target on Merus from $73.00 to $70.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price target on shares of Merus in a report on Monday, March 3rd. Piper Sandler started coverage on Merus in a research note on Thursday, February 13th. They set an “overweight” rating and a $84.00 price objective for the company. Guggenheim restated a “buy” rating and issued a $109.00 price target on shares of Merus in a research note on Friday, March 28th. Finally, Needham & Company LLC cut their price objective on shares of Merus from $85.00 to $83.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Merus has a consensus rating of “Buy” and an average target price of $85.31.

Merus Stock Down 8.7 %

The business’s 50 day simple moving average is $44.09 and its 200 day simple moving average is $45.86. The company has a market capitalization of $2.63 billion, a PE ratio of -9.65 and a beta of 1.02.

Merus (NASDAQ:MRUS) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The business had revenue of $9.14 million during the quarter, compared to the consensus estimate of $10.57 million. On average, analysts anticipate that Merus will post -3.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Merus by 17.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,200 shares of the biotechnology company’s stock worth $4,207,000 after acquiring an additional 12,212 shares during the period. HighTower Advisors LLC purchased a new stake in shares of Merus in the third quarter worth approximately $358,000. Wellington Management Group LLP boosted its holdings in shares of Merus by 73.6% during the third quarter. Wellington Management Group LLP now owns 2,887,514 shares of the biotechnology company’s stock worth $144,260,000 after purchasing an additional 1,224,573 shares during the period. KBC Group NV boosted its holdings in shares of Merus by 4,583.6% during the fourth quarter. KBC Group NV now owns 57,234 shares of the biotechnology company’s stock worth $2,407,000 after purchasing an additional 56,012 shares during the period. Finally, State of New Jersey Common Pension Fund D grew its position in Merus by 29.0% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 48,268 shares of the biotechnology company’s stock valued at $2,030,000 after purchasing an additional 10,842 shares in the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.